KR20200063772A - Composition for anti-inflammation comprising extract of mealworm containing ginsenoside Re - Google Patents

Abstract

The present invention relates to a composition for anti-inflammation containing a Neatus picipes larva extract as an active component. More specifically, the present invention relates to a composition for anti-inflammation containing a Neatus picipes larva extract, which contains ginsenoside Re having excellent NO production inhibitory activity in macrophages stimulated with lipopolysaccharide (LPS), as an active component.

Description

Composition for anti-inflammation comprising extract of mealworm containing ginsenoside Re}

The present invention relates to an anti-inflammatory composition comprising a mealworm larva extract as an active ingredient, specifically, a mealworm larva extract comprising ginsenoside Re having excellent NO production inhibitory activity in macrophages stimulated with lipopolysaccharide (LPS). It relates to an anti-inflammatory composition comprising as an active ingredient.

Inflammation is a local biological defense response that appears in response to physical trauma, harmful chemicals, infections caused by bacteria, fungi, viruses, or pathological conditions caused by irritating substances in metabolites in vivo. Inflammation is triggered by a variety of inflammatory mediators produced from damaged tissue and migrating cells. During an inflammatory reaction, plasma accumulates in the inflamed area, diluting the toxicity secreted by bacteria, increasing blood flow, and accompanying symptoms such as erythema, pain, edema, and fever. In the normal case, the living body neutralizes or eliminates the onset factors through the inflammatory reaction and regenerates the upper tissue to restore normal structure and function, but in other cases, it progresses to a disease state such as chronic inflammation.

Although various biochemical phenomena are involved in the inflammatory reaction, macrophages are known to play an important role in the inflammatory reaction by generating nitric oxide (NO) and various inflammatory cytokines by chemical stimulation. Nitric oxide is synthesized from L-arginine by the action of nitric oxide synthase (NOS), and NOS has several isoforms. BNOS (brain NOS) present in the brain, nNOS (neuronal NOS) present in the nervous system, and eNOS (endothelial NOS) present in the vascular endothelial system are always expressed at a certain level in the body, and a small amount of monoxide produced by them Nitrogen (NO) plays an important role in maintaining homeostasis by performing various physiological reactions related to blood pressure regulation, neurotransmission, learning, and memory. On the other hand, iNOS (induced NOS), whose expression is induced by a certain stimulus, generates excessive NO, and nitric oxide generated excessively by iNOS reacts with superoxide to form peroxynitrite. It acts as a powerful oxidant, damaging cells, thereby participating in various pathological processes, including inflammation and cancer.

On the other hand, brown worms (Tenebrio molitor) larvae, also called wheat worms, are insects of the Coleoptera family, and are recognized as industrial insects because they can be used for edible, feed, and industrial purposes, unlike other types of worms (lesser mealworm). In addition, the larvae of the American king beetle (Zophobas morio), also called the super wheat worm, are larvae of the Coleoptera family and are significantly larger than the worm, and only the larval stage mainly used as food lasts for more than 4 months.

An object of the present invention is to provide a composition for anti-inflammatory comprising an larva larva extract having excellent NO production inhibitory activity in macrophages stimulated with LPS (lipopolysaccharide) as an active ingredient.

In addition, the present invention has another object to provide an anti-inflammatory drug and a health functional food comprising the anti-inflammatory composition according to the present invention.

The present invention provides an anti-inflammatory composition comprising an extract of a mealworm larva extracted from a mealworm larva raised by feeding a feed containing ginseng as an active ingredient.

According to an embodiment of the present invention, the mealworm larvae may be at least any one selected from brown mealworm larvae and American kingworm larvae.

In addition, according to an embodiment of the present invention, the ginseng may be at least any one selected from ginseng leaves and ginseng lightning.

In addition, according to an embodiment of the present invention, the ginseng may be included in 0.5 to 5.5% by weight based on the weight of the feed.

In addition, according to an embodiment of the present invention, the mealworm larva extract may be extracted from a brown mealworm larva raised by feeding a feed containing ginseng torpedo.

In addition, according to an embodiment of the present invention, the larva larva extract may be extracted from the larvae of American king larvae fed by feeding feed containing ginseng leaves or ginseng torpedoes.

In addition, according to an embodiment of the present invention, the larva larva extract may be extracted with 10 to 50% by volume of alcohol.

In addition, according to an embodiment of the present invention, the larva larva extract may be included in a concentration of 10 ~ 300μg / ml.

In addition, according to one embodiment of the present invention, the larva larva extract may include ginsenoside Re.

In addition, the present invention provides an anti-inflammatory drug comprising the anti-inflammatory composition according to the present invention.

In addition, the present invention provides an anti-inflammatory health functional food comprising the anti-inflammatory composition according to the present invention.

The anti-inflammatory composition according to the present invention can be widely used as an anti-inflammatory drug or a health functional food by including a larva larva extract excellent in NO production inhibitory activity in macrophages stimulated with lipopolysaccharide (LPS) as an active ingredient.

1A is a graph showing the results of LC analysis of a mealworm larva extract according to an embodiment and a comparative example of the present invention.
1B is a graph showing the results of LC analysis of a mealworm larva extract according to an embodiment and a comparative example of the present invention.
Figure 2a is a graph showing the results of measuring the cytotoxicity of the mealworm larva extract according to an embodiment and a comparative example of the present invention.
Figure 2b is a graph showing the results of measuring the cytotoxicity of the mealworm larva extract according to an embodiment and a comparative example of the present invention.
Figure 3a is a graph showing the results of measuring the NO inhibitory activity for the mealworm larva extract according to an embodiment and a comparative example of the present invention.
Figure 3b is a graph showing the results of measuring the NO inhibitory activity for the mealworm larva extract according to an embodiment and a comparative example of the present invention.
Figure 4a is a graph showing the result of measuring the solubility of the brown larva larvae reared according to the used feed (feed 1 ~ 9) according to the breeding example.
Figure 4b is a graph showing the weight of the chrysalis from the brown larvae bred according to the feed (feed 1 to 9) used according to the breeding example.
Figure 4c is a graph showing the period of brown larvae reared according to the feed (feed 1 to 9) used according to the breeding example.

An object of the present invention is to provide a composition for anti-inflammatory comprising an larva larva extract having excellent NO production inhibitory activity in macrophages stimulated with LPS (lipopolysaccharide) as an active ingredient.

In addition, the present invention has another object to provide an anti-inflammatory drug and a health functional food comprising the anti-inflammatory composition according to the present invention.

The term “composition” refers to a mixture of the larval larva extract of the present invention with other chemical components such as diluents or carriers.

The term “carrier” is defined as a compound that facilitates the addition of a compound into a cell or tissue. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into an organism's cells or tissues.

The term “diluent” is defined as a compound that dilutes in water that will dissolve the compound, as well as stabilize the biologically active form of the target compound. Salts dissolved in buffer solutions are used in the art as diluents. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of the compound.

All technical terms used in the present invention are used in the meaning as generally understood by those skilled in the art in the relevant field of the present invention, unless otherwise defined. Also, a preferred method or sample is described herein, but similar or equivalent ones are included in the scope of the present invention.

Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art to which the present invention pertains can easily practice. The present invention can be implemented in many different forms and is not limited to the embodiments described herein.

The composition for anti-inflammatory according to the present invention includes a mealworm larva extract extracted from a mealworm larvae fed by feeding a feed containing ginseng as an active ingredient.

The larva larvae, which are the extraction targets of the larval larva extract contained as an active ingredient in the anti-inflammatory composition according to the present invention, refer to the stage before hatching from an egg and becoming an adult.

In addition, because the larva larvae are fed and fed with ginseng, the active ingredient of ginseng containing ginsenoside Re is safely contained within the larval larvae, that is, the structure of ginsenoside Re does not change and can be maintained in the larval larvae. , As the active ingredient is also included in the larval larva extract after the extraction process, NO production inhibitory activity may be remarkably excellent in macrophages stimulated with lipopolysaccharide (LPS).

The larva larvae may be at least one selected from brown larva larvae and king larva larvae, and may be larvae larvae 8 to 13 weeks after the feed is supplied.

If feeder larvae are used for less than 8 weeks after feeding, there is a concern that the active ingredient containing ginsenoside Re in the larvae may be significantly less. In case of using feeder larvae that have been fed for more than 13 weeks, Caterpillars can be transformed into pupae or adults, or the content of active ingredients per weight of larvae may be significantly less.

The ginseng may be included in the feed in the form of powder obtained by grinding ginseng.

The ginseng may be at least one selected from ginseng leaves and ginseng torpedoes from the site of ginseng. Preferably, when the mealworm larvae are brown mealworm larvae, the ginseng may be ginseng torpedo, and the mealworm larva extract extracted from the brown mealworm larvae raised by feeding a feed containing ginseng fireweed may have an excellent anti-inflammatory effect. .

In addition, when the mealworm larvae are American kingworm larvae, the ginseng may be ginseng leaves or ginseng torpedoes. Can be significantly superior. More preferably, the larva larvae extract extracted from the American larvae reared by feeding a feed containing ginseng leaves may have a better anti-inflammatory effect.

The ginseng may be included in an amount of 0.5 to 5.5% by weight based on the weight of the feed, and the feed may further include wheat bran, cabbage for water supply, and the like.

When the ginseng is contained in an amount of less than 0.5% by weight based on the weight of the feed, the content of the active ingredient containing ginsenoside Re in the larvae larva extract may not be included in the desired level, so the anti-inflammatory effect may be incomplete. When included in excess of 5.5% by weight, the growth rate of the larva larvae may be lowered because the stock in the feed used for the breeding of the larva larvae is small, and accordingly, the yield of the larvae larvae decreases or the effective content of the larvae larvae. Content may be lowered.

Before extracting the larvae, the larvae may be dried, and the drying method may use a drying method of worms commonly used in the art, and may be, for example, hot air drying or freeze drying, but is not limited thereto.

In addition, the extraction process may be performed after crushing the larva larvae or dried larva larvae before extracting the larvae larvae, and the crushing method may use a pulverization method of a medicine or food commonly used in the art.

In addition, the mealworm larva extract is extracted with water and at least one selected from lower alcohols having 1 to 4 carbon atoms, preferably 10 to 50% by volume of alcohol, and more preferably 20 to 40% by volume of alcohol. It is possible to increase the content of ginsenoside Re in the extract.

The extraction method of the mealworm larva extract may use an extraction method commonly used in the art, and may be, for example, a heat extraction method, but is not limited thereto.

When the heat extraction method is used as an extraction method of the mealworm larva extract, it may be performed for 4 to 6 hours at 30 to 40°C.

After the extraction process is carried out, the solvent in the extraction solution may be removed using a solvent removal method commonly used in the art to obtain a mealy larva extract in the form of a powder, and a vacuum filtration method may be used as an example of a solvent removal method. However, it is not limited thereto.

In addition, the mealworm larva extract may be included in a concentration of 10 to 300 μg/ml in an anti-inflammatory composition, preferably 80 to 300 μg/ml, more preferably 120 to 300 μg/ml, and a concentration of less than 10 μg/ml When included as NO, the inhibitory activity is significantly low, so it may be difficult to express an anti-inflammatory effect at a desired level, and when included in a concentration exceeding 300 μg/ml, cytotoxicity may increase.

When the larva larva extract is included in the anti-inflammatory composition at a concentration of 80 to 300 μg/ml, the anti-inflammatory effect may be further improved, and when included at a concentration of 120 to 300 μg/ml, the anti-inflammatory effect may be further improved. .

Meanwhile, the anti-inflammatory composition according to the present invention is formulated in the form of an oral dosage form such as a powder, a granule, a tablet, a capsule, a suspension, an emulsion, a syrup, an aerosol, an external preparation, a suppository, and a sterile injection solution, respectively, according to a conventional method. Can be used.

In addition, the anti-inflammatory composition is formulated in a unit dose form by using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by those skilled in the art to which the present invention pertains. It can be manufactured or can be manufactured by incorporating it into a multi-dose container.

The anti-inflammatory composition of the present invention may be included in a drug and utilized, and a pharmaceutically acceptable carrier included in the drug is commonly used in preparation, and lactose, dextrose, sucrose, sorbitol, and mannitol, Starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, Magnesium stearate and mineral oil, and the like, but is not limited thereto.

In addition, when the anti-inflammatory composition of the present invention is used in a pharmaceutical composition, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. may be additionally included. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

The drug may be administered orally or parenterally, and for parenteral administration, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration, etc. Can be. When administered orally, proteins or peptides are digested, so oral compositions must be formulated to coat the active agent or to protect it from degradation in the stomach. In addition, the active agent can be administered by any device capable of moving to the target cell.

Suitable dosages of these pharmaceuticals vary by factors such as formulation method, mode of administration, patient's age, weight, sex, morbidity, food, time of administration, route of administration, rate of excretion, and response sensitization, usually skilled The doctor can easily determine and prescribe a dose effective for the desired treatment or prevention.

The medicine may be administered as an individual prophylactic or therapeutic agent, or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.

Hereinafter, an example of preparing a powder containing the anti-inflammatory composition of the present invention as an active ingredient will be described, but the present invention is intended to be described in detail rather than to limit it.

<Production Example 1>

Poultry larva extract 100 mg

Lactose 100 mg

Talc 10 mg

The ingredients are mixed and filled in an airtight fabric to prepare a powder.

In addition, the present invention provides a health functional food comprising the anti-inflammatory composition according to the present invention.

The type of the health functional food composition is not particularly limited as long as it is usually manufactured and/or sold. For example, dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes It can be used in the form of pills, powders, granules, needles, tablets, capsules, or beverages, and includes all health functional foods in the ordinary sense.

The healthy beverage composition is not particularly limited to the liquid component except that it contains the anti-inflammatory composition according to the present invention, and may contain various flavoring agents or natural carbohydrates, etc., as additional components, like a conventional beverage.

Typically, the amount of jerk larva extract contained in the dietary supplement may be included in an amount of 0.01 to 20% by weight, preferably 0.01 to 10% by weight of the total food weight. In addition, in the case of long-term intake for the purpose of health and hygiene or for health control, it may be below the above range, and since there is no problem in terms of safety, the active ingredient may also be used in an amount above the above range.

Hereinafter, an example of preparing a health functional food containing the anti-inflammatory composition of the present invention will be described, but the present invention is intended to be described in detail rather than to limit it.

<Production Example 2>

Anti-inflammatory composition 200 mg

Vitamin A Acetate 70 μg

Vitamin E 1.0 mg

Vitamin B 1 0.13 mg

Vitamin B 2 0.15 mg

Vitamin B 6 0.5mg

Vitamin B 12 0.2 μg

Vitamin C 10 mg

Biotin10 ㎍

Nicotinic acid amide 1.7 mg

50 ㎍ folic acid

Calcium Pantothenate 0.5 mg

Ferrous sulfate 1.75 mg

Zinc oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium phosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

On the other hand, the present invention may provide a method for rearing the larvae, and the method for rearing the larvae of the present invention comprises a first step of preparing a feed containing ginseng and a second step of feeding the prepared larvae by feeding the prepared feed. Since it is bred for inclusion, the production yield of jerkery is excellent.

In this case, when ginseng contains 0.5 to 5.5% by weight based on the weight of the feed, not only is the solubility rate, which is the rate of stripping the larvae into pupae, the weight of the pupa separated from the larvae increases, the larval period This can be short.

In addition, the ginseng may be at least one selected from ginseng leaves and ginseng torpedoes, and preferably, when it is a ginseng leaf, not only has a high solubility rate, but also increases the weight of the pupa peeled from the larvae, and the larval period may be short. .

In addition, the leech larvae may be at least one selected from brown larva larvae and American king larvae, preferably brown larvae.

Furthermore, the method for breeding larvae of the present invention may have a solubility of 80% or more, preferably 90% or more. At this time, the solubilization rate represents the rate at which the larva leaves the pupa, and can be calculated by the following relational formula 1 based on 16 weeks of breeding larvae.

[Relationship 1]

Dissolution rate (%) = (Number of dissolved objects/survived objects) × 100

In addition, the method for rearing the larvae of the present invention is based on 16 weeks of breeding the larval larvae, and the pupa separated from the larvae may be 129.5 to 186 mg, and the larval period may be 78 to 102 days.

Hereinafter, the present invention will be described in more detail through the following examples. However, the following examples are merely examples for easily explaining the contents and scope of the technical spirit of the present invention, and the technical scope of the present invention is not limited or changed thereby. In addition, various modifications and changes are possible within the scope of the technical spirit of the present invention based on these examples can be easily determined by those skilled in the art.

(Example 1)

Ginseng leaf powder (1% by weight) and wheat bran (99% by weight) prepared by crushing ginseng leaves were fed together with cabbage for hydration for 10 weeks to breed brown larvae. The dried brown larva larvae were dried and pulverized, and heat-extracted with 30% by volume of alcohol to remove the solvent to obtain a brown larva larva extract.

(Example 2)

A feed consisting of ginseng torpedo powder (1% by weight) and wheat bran (99% by weight) prepared by crushing ginseng torpedoes was fed along with cabbage for hydration for 10 weeks to breed brown larvae. The dried brown larva larvae were dried and pulverized, and heat-extracted with 30% by volume of alcohol to remove the solvent to obtain a brown larva larva extract.

(Example 3)

It was carried out in the same manner as in Example 2, but was fed with feed consisting of ginseng lightning powder (5% by weight) and bran (95% by weight) to breed brown larvae.

(Example 4)

The same procedure as in Example 2 was carried out, but a feed consisting of ginseng lightning powder (10% by weight) and wheat bran (90% by weight) was fed to breed brown larvae.

(Example 5)

It was carried out in the same manner as in Example 2, but was fed with feed consisting of ginseng lightning powder (20% by weight) and wheat bran (80% by weight) to breed brown larvae.

(Example 6)

Ginseng leaf powder (1% by weight) and wheat bran (99% by weight) prepared by crushing ginseng leaves were fed together with Chinese cabbage for hydration for 10 weeks to breed American king larvae. After drying the larvae of the reared American larvae, crushing them, heat-extracting them to 30% by volume, and then removing the solvent, to obtain the larvae of the American larvae.

(Example 7)

Feeding the feed consisting of ginseng torpedo powder (1% by weight) and wheat bran (99% by weight) prepared by crushing ginseng torpedoes along with Chinese cabbage for hydration for 10 weeks was used to breed American king-fly larvae. After the dried American king larvae were dried and pulverized, this was heat-extracted to 30% by volume, and then the solvent was removed to obtain an American king larva larvae extract.

(Comparative Example 1)

The feed consisting of wheat bran (100% by weight) was fed with cabbage for hydration for 10 weeks to breed brown larvae. The dried brown larva larvae were dried and pulverized, and heat-extracted with 30% by volume of alcohol to remove the solvent to obtain a brown larva larva extract.

(Comparative Example 2)

After the Comparative Example 1 and brown larvae were reared, the American larva larvae were bred, from which an American larvae larvae extract was obtained.

(Experimental Example 1) Survival rate

The survival rates of brown larvae raised in Examples 1 to 5 and Comparative Example 1 were evaluated, and the results are shown in Table 1 below.

Referring to Table 1, the mealy larvae fed with feed containing ginseng leaves or ginseng torpedoes were not metabolized, that is, they were not transformed into pupae, and the survival rate was also confirmed to be similar to the mealy larvae fed with feed only.

(Experiment 2) Ginsenoside Re content analysis

UPLC TOF/MS was used to analyze whether ginsenoside Re was contained in the mealworm larva extracts prepared in Example 1, Example 2, and Comparative Example 1, and the analysis results are shown in FIGS. 1A and 1B.

Referring to Figures 1a and 1b, it can be confirmed that the ginsenoside Re is present in the larva larva extract extracted from the brown larva larva and the American larva larva fed with a feed containing ginseng flower or ginseng leaves.

(Experiment 3) Cytotoxicity evaluation

Macrophage-Raw 264.7 was dispensed into a 96-well plate at a rate of 5000 cells/ml, and then cultured for 24 hours, followed by 100 and 200 of the mealworm larva extracts prepared in Examples 1, 2, 6, 7 and Comparative Examples 1 and 2. After treating the anti-inflammatory composition containing the concentration of μg/ml, incubated for 24 hours, and treated with MTS, absorbance was measured using a microplate reader at a wavelength of 490 nm.

The cytotoxicity measurement results are shown in FIGS. 2A and 2B.

Referring to Figures 2a and 2b, Example 1, 2 brown larva larvae extract and Examples 6, 7 of the American larvae larvae extract is determined that there is no cytotoxicity at a concentration of 100, 200 μg / ml, rather than cells It can be seen that the proliferation increases.

(Experimental Example 4) Evaluation of NO inhibitory activity

When macrophages are activated by an inflammatory mediator (LPS), changes in extracellular NO concentration were measured by using a point in which the amount of inflammatory molecules such as nitric oxide (NO) increases, and the results are shown in FIGS. 3A and 3B. Did. Compared to the normal group, the NO concentration of the LPS-treated group was increased by about 5.5 times, and as a result of treating the brown larva larva extract by type, Comparative Example 1 (no treatment group), Example 2 (brown meal + ginseng lightning), When treating the extract of Example 1 (brown meal + ginseng leaf), the NO concentration was reduced by about 4.4%, 32.8%, and 11.6%, respectively, compared to the LPS-only group. It was confirmed that the extract prepared in Example 2 (brown meal + ginseng torpedo) has significantly improved anti-inflammatory effect by reducing the amount of NO produced by LPS treatment.

In addition, the extract of larvae of the American kingfish according to Examples 6 and 7 had a significantly better NO inhibitory activity than the extract of Comparative Example 2, and in particular, the NO inhibitory activity of the extract of Example 6 (American kingfish + ginseng leaf) was the most. It was confirmed that it was excellent.

Breeding example: How to breed larvae

The feed was fed with the cabbage for hydration for 16 weeks to breed brown larvae. At this time, it was composed of ginseng leaf powder prepared by crushing the ginseng leaves constituting, ginseng lightning powder and bran produced by crushing ginseng torpedoes. Using, brown larvae were bred.

The solubility, pupa weight, and larval period of the brown larvae reared using the feeds described in Table 2 were measured, respectively, and the results are shown in FIGS. 4A to 4C and Table 3 below.

The dissolution rate was calculated by the following relational expression 1.

[Relationship 1]

Dissolution rate (%) = (Number of dissolved objects/survived objects) × 100

As can be seen in Table 3, when the feeder 2 (bran bran 99% by weight, ginseng leaf 1% by weight) was used to breed brown larvae, it was confirmed that the highest solubility rate was 100.0%.

In addition, it was confirmed that the pupa weight was highest when feeding brown larvae using feed 3 (bran bran 95% by weight, ginseng leaf 5% by weight).

In addition, it was confirmed that the larval period was the shortest when breeding brown larvae using feed 1 (100% by weight bran).

Although the preferred embodiments of the present invention have been described in detail above, the present invention is not limited to the specific embodiments described above, and is generally limited in the technical field to which the present invention pertains without departing from the gist of the present invention claimed in the claims. Of course, various modifications and improvements can be implemented by a person having knowledge of the above, and such modifications and improvements should not be individually understood from the technical idea or prospect of the present invention.

Claims (11)

An anti-inflammatory composition comprising an extract of a mealworm larva extracted from a mealworm larva raised by feeding a feed containing ginseng as an active ingredient.
According to claim 1,
The larva larvae are anti-inflammatory composition, characterized in that at least one selected from brown larva larvae and king larvae.
According to claim 1,
The ginseng is an anti-inflammatory composition, characterized in that at least one selected from ginseng leaves and ginseng lightning.
According to claim 1,
The ginseng is an anti-inflammatory composition, characterized in that contained in 0.5 to 5.5% by weight based on the weight of the feed.
According to claim 1,
The larva larva extract is an anti-inflammatory composition, characterized in that extracted from brown larva larvae raised by feeding a feed containing ginseng torpedo.
According to claim 1,
The larvae larva extract is an anti-inflammatory composition, characterized in that extracted from the American larvae larvae raised by feeding a feed containing ginseng leaves or ginseng torpedo.
According to claim 1,
Anti-inflammatory composition, characterized in that the larva larva extract is extracted with 10 to 50% by volume of alcohol.
According to claim 1,
Anti-inflammatory composition, characterized in that the larva larva extract is contained in a concentration of 10 ~ 250μg / ml.
According to claim 1,
The larvae larva extract is anti-inflammatory composition, characterized in that it comprises a ginsenoside Re.
An anti-inflammatory drug comprising the composition according to claim 1.
An anti-inflammatory health functional food comprising the composition according to claim 1.

Images